GenSight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa

GenSight Biologics Announces a Successful €1.0 Million Fundraising Supported by Existing Shareholders

GenSight Biologics Reports Cash Position as of September 30, 2026

GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates

GenSight Biologics Provides September 2026 Business Updates

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026

GenSight Biologics to hold its Combined General Meeting on May 19, 2026

GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments

GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026